Estradiol increases cell growth in human astrocytoma cell lines through ERα activation and its interaction with SRC-1 and SRC-3 coactivators

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 2, 2012, Pages 379-386

  González Arenas, Aliesha ^a   Hansberg Pastor, Valeria ^a   Hernández Hernández, Olivia Tania ^a   González García, Tania Karina ^a   Henderson Villalpando, Joshua ^a   Lemus Hernández, Diana ^a   Cruz Barrios, Aglaé ^a   Rivas Suárez, Mariana ^a   Camacho Arroyo, Ignacio ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Astrocytoma; Coactivator; ER ; RNA interference; SRC 1; SRC 3

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; VASCULOTROPIN;

ARTICLE; ASTROCYTOMA CELL; CANCER GRADING; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; RNA INTERFERENCE; TREATMENT DURATION; WESTERN BLOTTING;

ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CYCLIN D1; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HUMANS; NUCLEAR RECEPTOR COACTIVATOR 1; NUCLEAR RECEPTOR COACTIVATOR 3; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA INTERFERENCE;

EID: 84855810945     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.11.004     Document Type: Article

References (73)

1. Daumas-Duport C., Scheithauer B., O'Fallon J., Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988, 62:2152-2165.
2. Carroll R.S., Zhang J., Dashner K., Sar M., Black P.M. Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 1995, 37:496-503.
3. Gonzalez-Aguero G., Gutierrez A.A., Gonzalez-Espinosa D., Solano J.D., Morales R., Gonzalez-Arenas A., Cabrera-Munoz E., Camacho-Arroyo I. Progesterone effects on cell growth of U373 and D54 human astrocytoma cell lines. Endocrine 2007, 32:129-135.
4. Gonzalez-Aguero G., Ondarza R., Gamboa-Dominguez A., Cerbon M.A., Camacho-Arroyo I. Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res. Bull. 2001, 56:43-48.
5. Grunberg S.M., Weiss M.H., Spitz I.M., Ahmadi J., Sadun A., Russell C.A., Lucci L., Stevenson L.L. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J. Neurosurg. 1991, 74:861-866.
6. Schrell U.M., Adams E.F., Fahlbusch R., Greb R., Jirikowski G., Prior R., Ramalho-Ortigao F.J. Hormonal dependency of cerebral meningiomas. Part 1: Female sex steroid receptors and their significance as specific markers for adjuvant medical therapy. J. Neurosurg. 1990, 73:743-749.
7. Delbes G., Levacher C., Habert R. Estrogen effects on fetal and neonatal testicular development. Reproduction 2006, 132:527-538.
8. Deroo B.J., Buensuceso A.V. Minireview: Estrogen receptor-beta: mechanistic insights from recent studies. Mol. Endocrinol. 2010, 24:1703-1714.
9. Hewitt S.C., Korach K.S. Estrogen receptors: structure, mechanisms and function. Rev. Endocrinol. Metab. Disord. 2002, 3:193-200.
10. Nirmala P.B., Thampan R.V. Ubiquitination of the rat uterine estrogen receptor: dependence on estradiol. Biochem. Biophys. Res. Commun. 1995, 213:24-31.
11. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 2003, 11:695-707.
12. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1858-1862.
13. Weigel N.L. Steroid hormone receptors and their regulation by phosphorylation. Biochem. J. 1996, 319(Pt 3):657-667.
14. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270:1354-1357.
15. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14:121-141.
16. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20:321-344.
17. Wang S., Yuan Y., Liao L., Kuang S.Q., Tien J.C., O'Malley B.W., Xu J. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:151-156.
18. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
19. Tetel M.J. Nuclear receptor coactivators: essential players for steroid hormone action in the brain and in behaviour. J. Neuroendocrinol. 2009, 21:229-237.
20. Nishihara E., O'Malley B.W., Xu J. Nuclear receptor coregulators are new players in nervous system development and function. Mol. Neurobiol. 2004, 30:307-325.
21. Molenda H.A., Griffin A.L., Auger A.P., McCarthy M.M., Tetel M.J. Nuclear receptor coactivators modulate hormone-dependent gene expression in brain and female reproductive behavior in rats. Endocrinology 2002, 143:436-444.
22. Molenda-Figueira H.A., Murphy S.D., Shea K.L., Siegal N.K., Zhao Y., Chadwick J.G., Denner L.A., Tetel M.J. Steroid receptor coactivator-1 from brain physically interacts differentially with steroid receptor subtypes. Endocrinology 2008, 149:5272-5279.
23. Vienonen A., Miettinen S., Manninen T., Altucci L., Wilhelm E., Ylikomi T. Regulation of nuclear receptor and cofactor expression in breast cancer cell lines. Eur. J. Endocrinol. 2003, 148:469-479.
24. Weldon C.B., Elliott S., Zhu Y., Clayton J.L., Curiel T.J., Jaffe B.M., Burow M.E. Regulation of estrogen-mediated cell survival and proliferation by p160 coactivators. Surgery 2004, 136:346-354.
25. Kishimoto H., Wang Z., Bhat-Nakshatri P., Chang D., Clarke R., Nakshatri H. The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis 2005, 26:1706-1715.
26. Apostolakis E.M., Ramamurphy M., Zhou D., Onate S., O'Malley B.W. Acute disruption of select steroid receptor coactivators prevents reproductive behavior in rats and unmasks genetic adaptation in knockout mice. Mol. Endocrinol. 2002, 16:1511-1523.
27. Nishihara E., Yoshida-Komiya H., Chan C.S., Liao L., Davis R.L., O'Malley B.W., Xu J. SRC-1 null mice exhibit moderate motor dysfunction and delayed development of cerebellar Purkinje cells. J. Neurosci. 2003, 23:213-222.
28. Tognoni C.M., Chadwick J.G., Ackeifi C.A., Tetel M.J. Nuclear receptor coactivators are coexpressed with steroid receptors and regulated by estradiol in mouse brain. Neuroendocrinology 2011, 94:49-57.
29. Yore M.A., Im D., Webb L.K., Zhao Y., Chadwick J.G., Molenda-Figueira H.A., Haidacher S.J., Denner L., Tetel M.J. Steroid receptor coactivator-2 expression in brain and physical associations with steroid receptors. Neuroscience 2010, 169:1017-1028.
30. Grenier J., Trousson A., Chauchereau A., Cartaud J., Schumacher M., Massaad C. Differential recruitment of p160 coactivators by glucocorticoid receptor between Schwann cells and astrocytes. Mol. Endocrinol. 2006, 20:254-267.
31. Tetel M.J., Auger A.P., Charlier T.D. Who's in charge? Nuclear receptor coactivator and corepressor function in brain and behavior. Front. Neuroendocrinol. 2009, 30:328-342.
32. Sakakura C., Hagiwara A., Yasuoka R., Fujita Y., Nakanishi M., Masuda K., Kimura A., Nakamura Y., Inazawa J., Abe T., Yamagishi H. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int. J. Cancer 2000, 89:217-223.
33. Zhou H.J., Yan J., Luo W., Ayala G., Lin S.H., Erdem H., Ittmann M., Tsai S.Y., Tsai M.J. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005, 65:7976-7983.
34. Sakaguchi H., Fujimoto J., Sun W.S., Tamaya T. Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J. Steroid Biochem. Mol. Biol. 2007, 104:237-240.
35. Lonard D.M., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators and human disease. Endocr. Rev. 2007, 28:575-587.
36. Hernandez-Hernandez O.T., Rodriguez-Dorantes M., Gonzalez-Arenas A., Camacho-Arroyo I. Progesterone and estradiol effects on SRC-1 and SRC-3 expression in human astrocytoma cell lines. Endocrine 2010, 37:194-200.
37. Batistatou A., Stefanou D., Goussia A., Arkoumani E., Papavassiliou A.G., Agnantis N.J. Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J. Cancer Res. Clin. Oncol. 2004, 130:405-410.
38. Bozzetti C., Camisa R., Nizzoli R., Manotti L., Guazzi A., Naldi N., Mazza S., Nizzoli V., Cocconi G. Estrogen and progesterone receptors in human meningiomas: biochemical and immunocytochemical evaluation. Surg. Neurol. 1995, 43:230-233.
39. Honegger J., Renner C., Fahlbusch R., Adams E.F. Progesterone receptor gene expression in craniopharyngiomas and evidence for biological activity. Neurosurgery 1997, 41:1359-1363.
40. Omulecka A., Papierz W., Nawrocka-Kunecka A., Lewy-Trenda I. Immunohistochemical expression of progesterone and estrogen receptors in meningiomas. Folia Neuropathol. 2006, 44:111-115.
41. Halper J., Colvard D.S., Scheithauer B.W., Jiang N.S., Press M.F., Graham M.L., Riehl E., Laws E.R., Spelsberg T.C. Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays. Neurosurgery 1989, 25:546-552.
42. Kabat G.C., Etgen A.M., Rohan T.E. Do steroid hormones play a role in the etiology of glioma?. Cancer Epidemiol. Biomarkers Prev. 2010, 19:2421-2427.
43. Gonzalez-Arenas A., Aguilar-Maldonado B., Avendano-Vazquez S.E., Garcia-Sainz J.A. Estrogens cross-talk to alpha1b-adrenergic receptors. Mol. Pharmacol. 2006, 70:154-162.
44. Helguero L.A., Faulds M.H., Gustafsson J.A., Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616.
45. Merlo S., Frasca G., Canonico P.L., Sortino M.A. Differential involvement of estrogen receptor alpha and estrogen receptor beta in the healing promoting effect of estrogen in human keratinocytes. J. Endocrinol. 2009, 200:189-197.
46. Nakamura T., Katsu Y., Watanabe H., Iguchi T. Estrogen receptor subtypes selectively mediate female mouse reproductive abnormalities induced by neonatal exposure to estrogenic chemicals. Toxicology 2008, 253:117-124.
47. Cabrera-Munoz E., Gonzalez-Arenas A., Saqui-Salces M., Camacho J., Larrea F., Garcia-Becerra R., Camacho-Arroyo I. Regulation of progesterone receptor isoforms content in human astrocytoma cell lines. J. Steroid Biochem. Mol. Biol. 2009, 113:80-84.
48. Knizetova P., Ehrmann J., Hlobilkova A., Vancova I., Kalita O., Kolar Z., Bartek J. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 2008, 7:2553-2561.
49. Sallinen S.L., Sallinen P.K., Kononen J.T., Syrjakoski K.M., Nupponen N.N., Rantala I.S., Helen P.T., Helin H.J., Haapasalo H.K. Cyclin D1 expression in astrocytomas is associated with cell proliferation activity and patient prognosis. J. Pathol. 1999, 188:289-293.
50. Cicatiello L., Addeo R., Sasso A., Altucci L., Petrizzi V.B., Borgo R., Cancemi M., Caporali S., Caristi S., Scafoglio C., Teti D., Bresciani F., Perillo B., Weisz A. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol. Cell. Biol. 2004, 24:7260-7274.
51. Mueller M.D., Vigne J.L., Minchenko A., Lebovic D.I., Leitman D.C., Taylor R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:10972-10977.
52. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 2004, 10:331S-336S.
53. Gonzalez A., Martinez-Campa C., Mediavilla M.D., Alonso-Gonzalez C., Sanchez-Barcelo E.J., Cos S. Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells. Br. J. Cancer 2007, 97:755-760.
54. Barone T.A., Gorski J.W., Greenberg S.J., Plunkett R.J. Estrogen increases survival in an orthotopic model of glioblastoma. J. Neurooncol. 2009, 95:37-48.
55. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3:281-292.
56. Fox E.M., Davis R.J., Shupnik M.A. ERbeta in breast cancer-onlooker, passive player, or active protector?. Steroids 2008, 73:1039-1051.
57. Martin L.A., Pancholi S., Chan C.M., Farmer I., Kimberley C., Dowsett M., Johnston S.R. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Relat. Cancer 2005, 12:1017-1036.
58. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 2006, 281:9607-9615.
59. Karmakar S., Foster E.A., Smith C.L. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity. Endocrinology 2009, 150:1588-1596.
60. Louie M.C., Revenko A.S., Zou J.X., Yao J., Chen H.W. Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol. Cell. Biol. 2006, 26:3810-3823.
61. Tai H., Kubota N., Kato S. Involvement of nuclear receptor coactivator SRC-1 in estrogen-dependent cell growth of MCF-7 cells. Biochem. Biophys. Res. Commun. 2000, 267:311-316.
62. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 2003, 34:263-264.
63. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., Williams B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 2003, 5:834-839.
64. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr. Opin. Mol. Ther. 2007, 9:248-257.
65. Brierley M.M., Fish E.N. Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon Cytokine Res. 2002, 22:835-845.
66. Haque A., Das A., Hajiaghamohseni L.M., Younger A., Banik N.L., Ray S.K. Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol. Immunother. 2007, 56:615-625.
67. Qin L., Liu Z., Chen H., Xu J. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res. 2009, 69:3819-3827.
68. Cai D., Shames D.S., Raso M.G., Xie Y., Kim Y.H., Pollack J.R., Girard L., Sullivan J.P., Gao B., Peyton M., Nanjundan M., Byers L., Heymach J., Mills G., Gazdar A.F., Wistuba I., Kodadek T., Minna J.D. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010, 70:6477-6485.
69. Hamel W., Westphal M. Growth factors in gliomas revisited. Acta Neurochir. (Wien) 2000, 142:113-137.
70. Maiuri F., Del Basso De M., Caro A., Siciliano C., Peca P., Vergara G., Mariniello G.Pettinato Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival. Clin. Neuropathol. 2010, 29:109-114.
71. Ouafik L., Berenguer-Daize C., Berthois Y. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway. Cell. Signal. 2009, 21:597-608.
72. Navis A.C., Hamans B.C., Claes A., Heerschap A., Jeuken J.W., Wesseling P., Leenders W.P. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. J. Pathol. 2011, 223:626-634.
73. Schulte A., Gunther H.S., Phillips H.S., Kemming D., Martens T., Kharbanda S., Soriano R.H., Modrusan Z., Zapf S., Westphal M., Lamszus K. A distinct subset of glioma cell lines with stem cell-like properties reflects the transcriptional phenotype of glioblastomas and overexpresses CXCR4 as therapeutic target. Glia 2011, 59:590-602.